Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion

Journal of Endocrinology

Volumn 217, Issue 2, 2013, Pages 215-228

  Maity, Sangeeta ^a   Kar, Dipak ^a   De, Kakali ^a   Chander, Vivek ^a   Bandyopadhyay, Arun ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Cardiac dysfunction; Energy depletion; Fatty acid metabolism; Mitochondria; Thyroid hormone

Indexed keywords

ADENOSINE TRIPHOSPHATE; BEZAFIBRATE; CYTOCHROME C OXIDASE; LIOTHYRONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ENERGY EXPENDITURE; ENZYME ACTIVITY; FATTY ACID METABOLISM; FEMALE; GENE; GENE EXPRESSION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HYPERTHYROIDISM; NONHUMAN; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA GENE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BEZAFIBRATE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; FATTY ACIDS; FEMALE; HYPERTHYROIDISM; MITOCHONDRIA, HEART; OXIDATIVE STRESS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TRIIODOTHYRONINE;

EID: 84877347003     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0304     Document Type: Article

References (50)

1. Abel ED & Doenst T 2011 Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovascular Research 90 234-242. (doi:10.1093/cvr/cvr015)
2. Artal-SanzM& Tavernarakis N 2009 Prohibitin and mitochondrial biology. Trends in Endocrinology and Metabolism 20 394-401. (doi:10.1016/j.tem. 2009.04.004)
3. Ashrafian H, Redwood C, Blair E & Watkins H 2003 Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends in Genetics 19 263-268. (doi:10.1016/S0168-9525(03)00081-7)
4. Barger PM & Kelly DP 2000 PPAR signaling in the control of cardiac energy metabolism. Trends in Cardiovascular Medicine 10 238-245. (doi:10.1016/S1050-1738(00)00077-3)
5. van Bilsen M, van Nieuwenhoven FA & van der Vusse GJ 2009 Metabolic remodeling of the heart: beneficial or detrimental? Cardiovascular Research 81 420-428. (doi:101093/cvr/cvn282)
6. Blachy-Dyson E & Forte M 2001 VDAC channels. IUBMB Life 52 113-118. (doi:10.1080/15216540152845902)
7. Braunwald E & Bistrow MR 2000 Congestive heart failure: fifty years of progress. Circulation 102 IV-14-IV-23. (doi:10.1161/01.CIR.102. suppl_4.IV-14)
8. Cabrero A, Alegret M, Sanchez RM, Adzet T, Laguna JC & Carrera MV 2002 Increased reactive oxygen species production down-regulates peroxisome proliferator-activated pathway in C2C12 skeletal muscle cells. Journal of Biological Chemistry 277 10100-10107. (doi:10.1074/jbc. M110321200)
9. Chu G, Haghigh K & Kranias EG 2002 From mouse to man: understanding heart failure through genetically altered mouse models. Journal of Cardiac Failure 8 S432-S449. (doi:10.1054/jcaf.2002.129284)
10. Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA & Wright EG 2001 Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Experimental Cell Research 265 262-273. (doi:10.1006/excr.2001.5166)
11. Colombini M 2004 VDAC: the channel at the interface between mitochondria and the cytosol. Molecular and Cellular Biochemistry 256/257 107-115. (doi:10.1023/B:MCBI.0000009862.17396.8d)
12. Davidoff AJ, Mason MM, Davidson MB, Carmody MW, Hintz KK, Wold LE, Podolin DA & Ren J 2004 Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. American Journal of Physiology. Endocrinology and Metabolism 286 718-724. (doi:10.1152/ajpendo.00358.2003)
13. De K, Ghosh G, Datta M, Konar A, Bandyopadhyay J, Bandyopadhyay D, Bhattacharya S & Bandyopadhyay A 2004 Analysis of differentially expressed genes in hyperthyroid-induced hypertrophied heart by cDNA microarray. Journal of Endocrinology 182 303-314. (doi:10.1677/joe.0. 1820303)
14. Degens H, Glide AJ, Lindhout M, Willemsen PH, van der Vusse GJ & van BilsenM 2003 Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. American Journal of Physiology. Heart and Circulatory Physiology 284 H108-H115. (doi:10.1007/ s10741-008-9125-7)
15. Dillmann W 2010 Cardiac hypertrophy and thyroid hormone signaling. Heart Failure Reviews 15 125-132. (doi:10.1007/s10741-008-9125-7)
16. Drazner MH 2005 The transition from hypertrophy to failure: how certain are we? Circulation 112 936-938. (doi:10.1161/CIRCULATIONAHA. 105.558734)
17. Fadel BM, Ellahham S, Ringel MD, Lindsay J, Wartofsky L & Burman KD 2000 Hyperthyroid heart disease. Clinical Cardiology 23 402-408. (doi:10.1002/clc.4960230605)
18. Garcia JM 2010 Thyroid hormone and myocardial mitochondrial biogenesis. Vascular Pharmacology 52 120-130. (doi:10.1016/j.vph. 2009.10.008)
19. Garcia JM & Goldenthal MJ 2002 Understanding the impact of mitochondrial defects in cardiovascular disease: a review. Journal of Cardiac Failure 8 347-361. (doi:10.1054/jcaf.2002.127774)
20. Ghosh G, De K, Maity S, Bandyopadhyay D, Bhattacharya S, Reiter RJ & Bandyopadhyay A 2007 Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. Journal of Pineal Research 42 71-82. (doi:10.1111/j.1600-079X.2006. 00386.x)
21. Goffart S, Kliest-Retzow JCV & Wiesner RJ 2004 Regulation of mitochondrial proliferation in heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovascular Research 64 198-207. (doi:10.1016/j.cardiores.2004.06.030)
22. Goglia F, MorenoM& Lanni A 1999 Action of thyroid hormones at cellular level: themitochondrial target. FEBS Letters 452 115-120. (doi:10.1016/ S0014-5793(99)00642-0)
23. Gustafsson AB & Gottlieb RA 2008 Heart mitochondria: gates of life and death. Cardiovascular Research 77 334-343. (doi:10.1093/cvr/ cvm005)
24. Hunter JJ & Chien KR 1999 Signaling pathways for cardiac hypertrophy and failure. New England Journal of Medicine 341 1276-1283. (doi:10.1056/NEJM199910213411706)
25. Huss JM& Kelly DP 2004 Nuclear receptor signaling and cardiac energetics. Circulation Research 95 568-578. (doi:10.1161/01.RES.0000141774. 29937.e3)
26. Huss JM & Kelly DP 2005 Mitochondrial energy metabolism in heart failure: a question of balance. Journal of Clinical Investigation 115 547-555. (doi:10.1007/s10557-006-0643-z)
27. Hyyti OM & Portman MA 2006 Molecular mechanisms of crosstalk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart. Cardiovascular Drugs and Therapeutics 20 463-469. (doi:10.1007/s10557-006-0643-z)
28. Ingwall JS 2009 Energy metabolism in heart failure and remodelling. Cardiovascular Research 81 412-419. (doi:10.1093/cvr/cvn301)
29. Ingwall JS & Weiss RG 2004 Is the failing heart energy starved? On using chemical energy to support cardiac function Circulation Research 95 135-145. (doi:10.1161/01.RES.0000137170.41939d9)
30. Jonkers IJ, de Man FH, van der Laarse A, Frolich M, Gevers Leuven JA, Kamper AM, Blauw GJ & Smelt AH 2001 Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. Journal of Hypertension 19 749-755. (doi:10.1097/00004872-200104000-00012)
31. Kahaly GJ & Dillmann WH 2005 Thyroid hormone action in the heart. Endocrine Reviews 26 704-728. (doi:10.1210/er.2003-0033)
32. Kenzel V, Soukup T, Okruhlikova L', Slezak J & Tribulova N 2008 Thyroid hormones modulate occurrence and termination of ventricular fibrillation by both long-term and acute actions. Physiological Research 57(Suppl 2) S91-S96.
33. Kieck-Wilk B, Kieck AD, Olsazanecka A, Bodzioch M & Kawecka-Jaszcz K 2005 The selected pathophysiological aspects of PPARs activation. Journal of Physiology and Pharmacology 56 149-162.
34. Klein I & Ojamaa K 2001 Thyroid hormone and the cardiovascular system. New England Journal of Medicine 344 501-509. (doi:10.1056/ NEJM200105103441901)
35. Lefebvre P, Chinetti G, Fruchart JC & Staels B 2006 Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. Journal of Clinical Investigation 116 571-580. (doi:10.1172/JCI27989)
36. Lehman JJ & Kelly DP 2002 Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Failure Reviews 7 175-185. (doi:10.1023/A:1015332726303)
37. Lewis W, Haase CP, Raidel SM, Russ RB, Sutliff RL, Hoit BD & Samarel AM 2001 Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Laboratory Investigation 81 1527-1536. (doi:10.1038/labinvest.3780366)
38. Liao R, Nascimben L, Friedrich J, Gwathmey JK & Ingwall JS 1996 Decreased energy reserve in an animal model of dilated cardiomyopathy. Circulation Research 78 893-902. (doi:10.1161/01.RES.78. 5.893)
39. Luci S, Kluge H, Hirche F & Eder K 2006 Clofibrate increases hepatic triiodothyronine (T3)- and thyroxine (T4)-glucoronosyltransferase activities and lowers plasma T3 and T4 concentrations in pigs. Drug Metabolism and Disposition 34 1887-1892. (doi:10.1124/dmd.106. 011379)
40. Marín-García J, Goldenthala MJ & Moe GW 2001 Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovascular Research 52 103-110. (doi:10.1016/S0008-6363(01)00368-6)
41. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S & Kass DA 2008 Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nature Protocols 3 1422-1434. (doi:10.1038/nprot.2008.138)
42. Pinz I, Tian R, Belke D, Swanson E, Dillmann W & Ingwall JS 2011 Compromised myocardial energetic in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2A. Journal of Biological Chemistry 286 10163-10168. (doi:10.1074/jbc.M110.210757)
43. Rodriguez-Gomez I, Cruz A, Moreno JM, Soler A, Osuna A & Vargas F 2008 Clofibrate prevents and reverses the hemodynamic manifestations of hyperthyroidism in rats. American Journal of Hypertension 21 341-347. (doi:10.1038/ajh.2007.58)
44. Sarma S, Ardehali H & Gheorghiade M 2012 Enhancing the metabolic substrate: PPAR-a agonists in heart failure. Heart Failure Reviews 17 35-43. (doi:10.1007/s10741-010-9208-0)
45. Shohet RV, Kisanuki YY, Zhao XS, Siddiquee Z & Franco F 2004 Mice with cardiomyocyte specific disruption of endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. PNAS 101 2088-2093. (doi:10.1073/pnas.0307159101)
46. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N & Arbel N 2010 VDAC, a multi-functional mitochondrial protein regulating cell life and death. Molecular Aspects of Medicine 31 227-285. (doi:10.1016/j.mam.2010.03.002)
47. Tsutsui H, Kinugawa S & Matsushima S 2009 Mitochondrial oxidative stress and dysfunction in myocardial remodeling. Cardiovascular Research 81 449-456. (doi:10.1093/cvr/cvn280)
48. Ventura-Clapier R, Garnier A & Veksler V 2003 Energy metabolism in heart failure. Journal of Physiology 555 1-13. (doi:10.1113/jphysiol.2003. 055095)
49. Yen PM2001 Physiological and molecular basis of thyroid hormone action. Physiological Reviews 81 1097-1130.
50. Zhang J, Liem DA, Mueller M, Wang Y, Zong C, Deng N, Vondriska TM, Korge P, Drews O, Maclellan WR et al. 2008 Altered proteome biology of cardiac mitochondria under stress conditions. Journal of Proteome Research 7 2204-2214. (doi:10.1021/pr070371f)